|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||39.73 - 40.24|
|52 Week Range||38.14 - 50.65|
|PE Ratio (TTM)||9.68|
|Forward Dividend & Yield||1.64 (4.12%)|
|1y Target Est||48.00|
Regeneron Pharmaceuticals’ (REGN) Eylea injection has been approved for the treatment of wet AMD (age-related macular degeneration), DME (diabetic macular edema), and macular edema post-retinal vein occlusion. Regeneron is collaborating with Bayer for the global development and commercialization of Eylea outside the US market.
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
believe that many investors under-appreciate Sanofi’s non-diabetes businesses and think that the strength from the rest of the company will provide plenty of opportunity for upside, including the new acquisitions and pipeline. The recent slide in shares makes SNY an attractive purchase in our eyes.
On February 15, 2018, Teva Pharmaceutical (TEVA) stock registered a rise of ~10.5% in pre-market trading on the disclosure of Berkshire Hathaway’s (BRK) investment of $358 million in the stock at the end of 4Q17. Berkshire Hathaway’s investment in Teva bodes well for Teva investors. Given that Berkshire Hathaway’s investments are based on founder Warren Buffet’s value investing strategy, Teva is now seen as a fundamental value investment.
The future of the expensive new cholesterol drugs largely depends on the results of the Sanofi/Regeneron ODYSSEY Outcomes trial coming out next month.
In fiscal 2017, Pfizer’s (PFE) Medrol generated revenues of $483 million, which was ~7% higher on a YoY (year-over-year) basis. In 2017, in the US and in international markets, Medrol reported revenues of $317 million and $167 million, respectively, which was ~11% and ~1% higher on a YoY basis. In 4Q17, Medrol reported revenues of $131 million, which represents a ~10% YoY rise and a 20% quarter-over-quarter rise.
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
The lethal H3N2 flu strain and comorbid diseases claimed at least 4,000 lives in the U.S. last week, according to the Centers for Disease Control. The illness rate now rivals that of the swine flu in 2009 ...
Stocks that lose more than 90% of their value have an uphill climb to earn investors’ trust again. In the case of MannKind Corporation (NASDAQ:MNKD) it’s now been more than two years, but MNKD stock still is no buy. From June 2014 to January 2016, MNKD stock all but evaporated, plummeting from $52 to $3.
M&A poses downside risks to the credit quality of Europe's six largest pharmaceutical companies in 2018 and will likely dampen any benefits from expected improvements in operating performance in the coming ...
On January 30, 2018, Fitch Ratings reiterated its negative outlook on Sanofi with a rating of “AA-.” The rating agency views Sanofi’s two recent acquisitions in close succession with a total value of 13.7 billion euros as a risk to its balance sheet. According to Fitch, Sanofi’s FFO (funds from operations) adjusted net leverage is likely to rise to 2.2x due to its recent acquisitions of Bioverativ and Ablynx (ABLX). Fitch expects better clarity from Sanofi on the deal’s implications after Sanofi announces its 2017 results on February 7, 2018.